Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of O-(tetrahydropyrrole) ethyl derivative of cleistanthus sumatranus ketone in preparation of medicine for treating or preventing renal fibrosis

A technology of tetrahydropyrrolyl and ethyl derivatives, which can be used in pharmaceutical combinations, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve problems such as low safety and high toxicity, and achieve good resistance to renal fibrosis. Effect

Inactive Publication Date: 2014-12-10
于钦密
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The existing drugs for the treatment of renal fibrosis have the problems of high toxicity and low safety. It is of great value to find compounds or lead compounds from natural products and carry out structural modification to obtain their derivatives, so as to obtain potential drugs with high efficiency and low toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of O-(tetrahydropyrrole) ethyl derivative of cleistanthus sumatranus ketone in preparation of medicine for treating or preventing renal fibrosis
  • Application of O-(tetrahydropyrrole) ethyl derivative of cleistanthus sumatranus ketone in preparation of medicine for treating or preventing renal fibrosis
  • Application of O-(tetrahydropyrrole) ethyl derivative of cleistanthus sumatranus ketone in preparation of medicine for treating or preventing renal fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1 Preparation of Compound Cleistanone

[0018] The preparation method of the compound Cleistanone (I) refers to the literature published by Van Trinh Thi Thanh et al. , pages 4108–4111, August 2011).

[0019]

Embodiment 2

[0020] Example 2 Synthesis of O-Bromoethyl Derivatives (II) of Cleistanone

[0021] Compound I (440 mg, 1.00 mmol) was dissolved in 10 mL of benzene, and tetrabutylammonium bromide (TBAB) (0.04 g), 1,2-dibromoethane (3.760 g, 20.00 mmol) and 6 mL of 50% sodium hydroxide solution. The mixture was stirred at 25 °C for 24 h. After 24 hours, the reaction solution was poured into ice water, extracted twice with dichloromethane immediately, and the organic phase solutions were combined. Then the organic phase solution was washed with water and saturated brine three times successively, then dried with anhydrous sodium sulfate, and finally concentrated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: petroleum ether / acetone=100:1, v / v), and the yellow concentrated elution band was collected to obtain compound II as a yellow solid (344 mg, 63%).

[0022] 1H NMR (500MHz, DMSO-d 6...

Embodiment 3

[0026] Example 3 Synthesis of O-(tetrahydropyrrolyl) ethyl derivatives (III) of cleistanone Cleistanone

[0027] Compound II (273 mg, 0.5 mmol) was dissolved in 20 mL of acetonitrile, anhydrous potassium carbonate (345 mg, 2.5 mmol), potassium iodide (84 mg, 0.5 mmol) and pyrrolidine (1420 mg, 20 mmol) were added thereto, and the mixture was heated to reflux for 8 h. After the reaction was completed, the reaction solution was poured into ice water, extracted three times with an equal amount of dichloromethane, and the organic phases were combined. The combined organic phases were successively washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: petroleum ether / acetone=100:1, v / v), and the light yellow concentrated elution band was collected to obtain the O-(tetrahydropyrrolyl)ethyl deri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the fields of organic synthesis and medicinal chemistry, and particularly relates to an O-(tetrahydropyrrole) ethyl derivative of cleistanthus sumatranus ketone Cleistanone, a preparation method and an application of the O-(tetrahydropyrrole) ethyl derivative in preparation of a medicine for preventing or treating renal fibrosis. The invention synthesizes a novel O-(tetrahydropyrrole) ethyl derivative of the cleistanthus sumatranus ketone Cleistanone, and discloses a preparation method of the O-(tetrahydropyrrole) ethyl derivative. A pharmacology experiment shows that the O-(tetrahydropyrrole) ethyl derivative of the cleistanthus sumatranus ketone Cleistanone has the effect of preventing or treating the renal fibrosis, and has the value of developing the medicine for preventing or treating the renal fibrosis.

Description

technical field [0001] The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to O-(tetrahydropyrrolyl)ethyl derivatives of cleistanone, a preparation method and uses thereof. Background technique [0002] Renal fibrosis (including renal interstitial fibrosis and glomerulosclerosis) is the main pathological basis of the final stage of renal damage caused by various reasons. Proliferation and activation of stromal cells are related to the imbalance of vasoactive substances, cytokines and extracellular matrix transformation. Renal interstitial fibrosis is almost a common path for all primary or secondary renal diseases to progress to end-stage renal failure. It is urgent to develop anti-renal fibrosis drugs with high efficiency and low toxicity. [0003] The existing drugs for the treatment of renal fibrosis have the problems of high toxicity and low safety. It is of great value to find compounds or lead compounds from natural products...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/58A61P13/12C07J63/00
Inventor 江春平黄蓉吴俊华
Owner 于钦密
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com